Obesity drug trial pulled before it even started
NCT ID NCT06970405
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study was designed to test an experimental drug called garetosmab in otherwise healthy men and postmenopausal women with obesity. The goal was to check the drug's safety and how it affects hormones and blood clotting. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
garetosmab (an experimental drug)
What could go wrong
The study was withdrawn before any participants were enrolled, so no data was collected. It is unknown if garetosmab would have been safe or effective for obesity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.